Summary
Carvedilol Phosphate has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Heart Failure would be drug repurposing rather than first-in-human development. This does not mean it is approved for Heart Failure. ClinicalTrials.gov lists 2 registered trials linking Carvedilol Phosphate to Heart Failure: 1 has completed; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 3 (NCT00123903). It plans or enrolled 1220 participants. Registration activity spans 2005 to 2008. The literature layer holds 2 publications for this pair: 2 clinical trial publications. Publication years run from 2009 to 2017. These are primary trial reports rather than syntheses, so results have not yet been pooled or graded independently.
The RepurpOS disease-intelligence file for Heart Failure ranks 616 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Annual mortality ~22% on standard care; only 5-11% of HFrEF patients achieve normalisation of ejection fraction (HFrecEF) with GDMT; HFpEF has no disease-modifying therapy.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 29.5 (trials 5.5, literature 4.0, tier 15, approved bonus 5.0) |
| Registered trials | 2 total: 0 recruiting, 0 active / not yet recruiting, 1 completed, 1 other |
| Linked publications | 2 (2 clinical trial publications) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | inhibitor |
| Data sources | DGIdb |
| Linked via biomarker / target | ADRB3 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT00123903 | COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria 2005 | terminated | Phase 3 | 1,220 |
| NCT00742508 | A Phase I/II Clinical Study of SK&F-105517-D in Japanese Patients With Chronic Heart Failure 2008 | completed | Phase 1 | 41 |
Published literature
- Clinical trial publication Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trialGuglin M, Munster P, Fink A et al. · American heart journal · 2017 · PMID 28577685
- Clinical trial publication Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) TrialUdelson JE, Pressler SJ, Sackner-Bernstein J et al. · Journal of cardiac failure · 2009 · PMID 19477398
Mechanism and notes
Recorded mechanism or class: inhibitor.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target ADRB3. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Carvedilol Phosphate approved for Heart Failure?
Carvedilol Phosphate has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Heart Failure would be drug repurposing rather than first-in-human development. This does not mean it is approved for Heart Failure. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Carvedilol Phosphate in clinical trials for Heart Failure?
ClinicalTrials.gov lists 2 registered trials linking Carvedilol Phosphate to Heart Failure: 1 has completed; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 3 (NCT00123903). It plans or enrolled 1220 participants. Registration activity spans 2005 to 2008.
What does the evidence show for Carvedilol Phosphate in Heart Failure?
Carvedilol Phosphate has 1 completed trial and 2 linked publications for Heart Failure. Completed trials may or may not have posted results; follow the NCT links to check. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target ADRB3. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.